Kagocel® (Kagocel®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceKagocelKagocel
Similar drugsTo uncover
  • Kagocel®
    pills inwards 
    NEARMEDIC PLUS, LLC     Russia
    • Dosage form: & nbsppills
    Composition:

    Composition per 1 tablet: Active substance: kagocel (in terms of dry matter) - 12 mg. Auxiliary substances: potato starch - 10 mg, calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate - from 91% to 95%, povidone (Kollidon 30) - from 3.0% to 4.0%, crospovidone Kollidon CL) - 3.0% to 4.0%) - to obtain a tablet weighing 100 mg.

    Description:

    Tablets from white with a brownish tint to light-brown round biconvex with patches of brown.

    Pharmacotherapeutic group:Antiviral agent
    ATX: & nbsp

    J.05.A.X   Other antiviral drugs

    Pharmacodynamics:

    The main mechanism of action of the drug Kagocel is the ability to induce the production of interferons. Kagocel causes the formation in the human body of so-called late interferons, which are a mixture of α- and β-interferons with high antiviral activity. Kagocel causes the production of interferons in virtually all cell populations that participate in the antiviral response of the body: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When administered in one dose of the drug Kagocel the interferon titer in serum reaches its maximum values ​​after 48 hours. The interferon response of the body to the administration of kagocel is characterized by a prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of accumulation of interferons in the intestine when ingested kagocel does not coincide with the dynamics of circulating interferon titers. In the blood serum, interferon production reaches high values ​​only 48 hours after the administration of kagocel, while in the intestine the maximum production of interferons is observed after 4 hours.

    A drug Kagocel, when administered in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, it is not carcinogenic and does not have an embryotoxic effect.

    The greatest effectiveness in the treatment of the drug Kagocel is reached at its or his appointment not later than 4 day from the beginning of an acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the causative agent of the infection.

    Pharmacokinetics:

    24 hours after the introduction into the body kagocel accumulates, mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, lymph nodes. Low concentration is noted in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of kagocel in the brain is explained by the high molecular weight of the drug, which hinders its penetration through the blood-brain barrier. In blood plasma the preparation is mainly in a bound form.

    With daily repeated administration of Kagocelum, the volume of distribution varies widely within all organs studied. The accumulation of the drug in the spleen and lymph nodes is especially pronounced. When administered orally, about 20% of the administered dose of the drug enters the total blood flow. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is about 16%.

    Excretion: the body is excreted from the body, mainly through intestine: after 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestine and 10% by the kidneys. In the exhaled air the drug was not detected.

    Indications:

    A drug Kagocel are used in adults and children aged 3 years as a preventive and curative remedy for influenza and other acute respiratory viral infections (ARVI), and also as a remedy for herpes in adults.

    Contraindications:

    - Pregnancy and the period of breastfeeding;

    - Age to 3 years;

    - Hypersensitivity to the components of the drug;

    - Deficiency of lactase, lactose intolerance, glucose-galactose malabsorption.

    Carefully:
    Pregnancy and lactation:

    Due to the lack of necessary clinical data, the drug is contraindicated in pregnancy and during breastfeeding.

    Dosing and Administration:

    Inside, regardless of food intake.

    For the treatment of influenza and SARS, adults are prescribed in the first two days - 2 tablets 3 times a day, in the next two days - one tablet 3 times a day. There are 18 tablets per course, and the duration of the course is 4 days.

    Prevention of influenza and ARVI in adults is carried out by 7-day cycles: two days - 2 tablets 1 time per day, 5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.

    For the treatment of herpes in adults, appoint 2 tablets 3 times a day for 5 days. A total of 30 tablets per course, the duration of the course is 5 days.

    To treat influenza and SARS, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, the next two days - one tablet once a day. There are 6 tablets per course, and the duration of the course is 4 days.

    To treat influenza and SARS, children aged 6 years are prescribed in the first two days - 1 tablet 3 times a day, in the next two days - one tablet 2 times a day. There are 10 tablets per course, and the course duration is 4 days.

    Prevention of influenza and ARVI in children aged 3 years is carried out 7-day cycles: two days - 1 tablet 1 time per day, 5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.

    If there is no improvement after treatment, or the symptoms worsen, or new symptoms appear, it is necessary to consult a doctor.

    Use the drug only according to the indications, the method of administration and the doses indicated in the instructions.

    Side effects:

    Perhaps the development of allergic reactions.

    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, inform the doctor about it.

    Overdose:In case of an accidental overdose, it is recommended to prescribe a generous drink, induce vomiting.

    Interaction:A drug Kagocel is well combined with other antiviral drugs, immunomodulators and antibiotics (additive effect).
    Special instructions:To achieve a therapeutic effect, the drug should be taken no later than the fourth day after the onset of the disease.

    Effect on the ability to drive transp. cf. and fur:The effect of the drug on the ability to drive vehicles and mechanisms has not been studied.
    Form release / dosage:Tablets, 12 mg.

    Packaging:For 10 tablets in a contour mesh package made of PVC / PVDC film (polyvinyl chloride / polyvinylidene chloride - PVC/PVDC) and aluminum foil with a heat-sealable coating.

    1, 2 or 3 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years.

    After the expiry date indicated on the package, the drug should not be used.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N002027 / 01
    Date of registration:19.11.2007 / 17.01.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:NEARMEDIC PLUS, LLC NEARMEDIC PLUS, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp22.09.2017
    Illustrated instructions
      Instructions
      Up